Literature DB >> 30194029

Inhibition of collapsin response mediator protein-2 phosphorylation ameliorates motor phenotype of ALS model mice expressing SOD1G93A.

Yurika Numata-Uematsu1, Shuji Wakatsuki1, Seiichi Nagano2, Megumi Shibata1, Kazuhisa Sakai3, Noritaka Ichinohe3, Katsuhiko Mikoshiba4, Toshio Ohshima5, Naoya Yamashita6, Yoshiro Goshima7, Toshiyuki Araki8.   

Abstract

Amyotrophic lateral sclerosis (ALS) is an adult-onset neurological disease characterized by the selective degeneration of motor neurons leading to paralysis and immobility. Missense mutations in the gene coding for the Cu2+/Zn2+ superoxide dismutase 1 (SOD1) accounts for 15-20% of familial ALS, and mice overexpressing ALS-linked SOD1 mutants have been frequently used as an animal model for ALS. Degeneration of motor neurons in ALS progresses in a manner called "dying back", in which the degeneration of synapses and axons precedes the loss of cell bodies. Phosphorylation of collapsin response mediator protein 2 (CRMP2) is implicated in the progression of neuronal/axonal degeneration of different etiologies. To evaluate the role of CRMP2 phosphorylation in ALS pathogenesis, we utilized CRMP2 S522A knock-in (CRMP2ki/ki) mice, in which the serine residue 522 was homozygously replaced with alanine and thereby making CRMP2 no longer phosphorylatable by CDK5 or GSK3B. We found that the CRMP2ki/ki/SOD1G93A mice showed delay in the progression of the motor phenotype compared to their SOD1G93-Tg littermates. Histological analysis revealed that the CRMP2ki/ki/SOD1G93A mice retained more intact axons and NMJs than their SOD1G93A-Tg littermates. These results suggest that the phosphorylation of CRMP2 may contribute to the axonal degeneration of motor neurons in ALS.
Copyright © 2018 Elsevier B.V. and Japan Neuroscience Society. All rights reserved.

Entities:  

Keywords:  ALS; Axonal degeneration; CRMP2; Neuromuscular junction

Mesh:

Substances:

Year:  2018        PMID: 30194029     DOI: 10.1016/j.neures.2018.08.016

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  5 in total

1.  Inhibition of Crmp1 Phosphorylation at Ser522 Ameliorates Motor Function and Neuronal Pathology in Amyotrophic Lateral Sclerosis Model Mice.

Authors:  Tetsuya Asano; Haruko Nakamura; Yuko Kawamoto; Mikiko Tada; Yayoi Kimura; Hiroshi Takano; Ryoji Yao; Hiroya Saito; Takuya Ikeda; Hiroyasu Komiya; Shun Kubota; Shunta Hashiguchi; Keita Takahashi; Misako Kunii; Kenichi Tanaka; Yoshio Goshima; Fumio Nakamura; Hideyuki Takeuchi; Hiroshi Doi; Fumiaki Tanaka
Journal:  eNeuro       Date:  2022-05-23

2.  Deciphering the Proteome Dynamics during Development of Neurons Derived from Induced Pluripotent Stem Cells.

Authors:  Suzy Varderidou-Minasian; Bert M Verheijen; Philipp Schätzle; Casper C Hoogenraad; R Jeroen Pasterkamp; Maarten Altelaar
Journal:  J Proteome Res       Date:  2020-05-15       Impact factor: 4.466

3.  Molecular Mechanism for PACAP 38-Induced Neurite Outgrowth in PC12 Cells.

Authors:  Junko Shibato; Fumiko Takenoya; Takahiro Hirabayashi; Ai Kimura; Michio Yamashita; Ichiro Takasaki; Randeep Rakwal; Seiji Shioda
Journal:  Neural Plast       Date:  2021-08-07       Impact factor: 3.599

4.  Phosphorylated CRMP1, axon guidance protein, is a component of spheroids and is involved in axonal pathology in amyotrophic lateral sclerosis.

Authors:  Yuko Kawamoto; Mikiko Tada; Tetsuya Asano; Haruko Nakamura; Aoi Jitsuki-Takahashi; Hiroko Makihara; Shun Kubota; Shunta Hashiguchi; Misako Kunii; Toshio Ohshima; Yoshio Goshima; Hideyuki Takeuchi; Hiroshi Doi; Fumio Nakamura; Fumiaki Tanaka
Journal:  Front Neurol       Date:  2022-09-27       Impact factor: 4.086

5.  Neuronal Conditional Knockout of Collapsin Response Mediator Protein 2 Ameliorates Disease Severity in a Mouse Model of Multiple Sclerosis.

Authors:  Aubin Moutal; Sergey Kalinin; Kathy Kowal; Natalia Marangoni; Jeffrey Dupree; Shao Xia Lin; Kinga Lis; Lucia Lisi; Kenneth Hensley; Rajesh Khanna; Douglas L Feinstein
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.